{"id":"foraseq","safety":{"commonSideEffects":[{"rate":null,"effect":"Tremor"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Palpitations"},{"rate":null,"effect":"Oral candidiasis"},{"rate":null,"effect":"Nervousness"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The drug combines an inhaled corticosteroid (ICS) to reduce airway inflammation with a long-acting beta-2 agonist (LABA) to provide bronchodilation. This dual mechanism addresses both the inflammatory and obstructive components of chronic respiratory disease, improving airway function and reducing exacerbations.","oneSentence":"Foraseq is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:13:20.134Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Maintenance treatment of asthma"},{"name":"Maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease)"}]},"trialDetails":[{"nctId":"NCT01167010","phase":"PHASE3","title":"A Non-inferiority, Comparative Study Between Foraseq®, Eurofarma´s Formoterol/Budesonide and Alenia® in Asthma","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2011-04","conditions":"Asthma","enrollment":552},{"nctId":"NCT01202084","phase":"PHASE3","title":"A Study Comparative of Formoterol/Fluticasone Foraseq® and Fluticasone in Asthma Patients","status":"COMPLETED","sponsor":"Eurofarma Laboratorios S.A.","startDate":"2012-01","conditions":"Asthma","enrollment":222}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Formoterol/Budesonide"],"phase":"phase_3","status":"active","brandName":"Foraseq®","genericName":"Foraseq®","companyName":"Eurofarma Laboratorios S.A.","companyId":"eurofarma-laboratorios-s-a","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Foraseq is a fixed-dose combination inhaled corticosteroid and long-acting beta-2 agonist for maintenance treatment of asthma and COPD. Used for Maintenance treatment of asthma, Maintenance treatment of COPD (Chronic Obstructive Pulmonary Disease).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}